How ElevateBio plans to create portfolio of cell, gene therapy newcos with $150M MPM, F2-led round

With $150 million in series A funding and an executive team led by Alexion and bluebird veterans, ElevateBio emerged from stealth on Monday with plans to accelerate cell and gene therapy discovery and development by building companies with access to fully integrated process development and manufacturing capacity, and then connecting them with investors to spin them out.

The round was co-led by MPM Capital's UBS Oncology Impact Fund and F2 Ventures, with participation from EcoR1 Capital, Redmile Group and Samsara BioCapital...